NASDAQ:NVUS - Novus Therapeutics Stock Price, Forecast & News

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

Novus Therapeutics Inc (NASDAQ:NVUS) released its quarterly earnings data on Wednesday, November, 13th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.41) by $0.19. View Novus Therapeutics' Earnings History.

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Novus Therapeutics.

2 analysts have issued 12-month price objectives for Novus Therapeutics' stock. Their forecasts range from $2.00 to $10.00. On average, they anticipate Novus Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 769.6% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

News articles about NVUS stock have been trending extremely negative this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novus Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Novus Therapeutics.

Novus Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 60,000 shares, an increase of 482.5% from the December 15th total of 10,300 shares. Based on an average daily volume of 131,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.5% of the company's stock are short sold. View Novus Therapeutics' Current Options Chain.

Some companies that are related to Novus Therapeutics include RegeneRx Biopharmaceuticals (RGRX), Alimera Sciences (ALIM), Citius Pharmaceuticals (CTXR), Pulmatrix (PULM), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Generex Biotechnology (GNBT), Vistagen Therapeutics (VTGN), AzurRx BioPharma (AZRX), Aptevo Therapeutics (APVO), Akari Therapeutics (AKTX), Spring Bank Pharmaceuticals (SBPH), Addex Therapeutics (ADDXF), Unum Therapeutics (UMRX), Fibrocell Science (FCSC) and VIVUS (VVUS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), TherapeuticsMD (TXMD), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Rigel Pharmaceuticals (RIGL), Tetraphase Pharmaceuticals (TTPH), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVUS stock can currently be purchased for approximately $0.69.

Novus Therapeutics has a market capitalization of $8.95 million. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. View Additional Information About Novus Therapeutics.

The official website for Novus Therapeutics is http://novustherapeutics.com/.

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]